Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Public ClinicalTrials.gov record NCT04947319. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Study identification
- NCT ID
- NCT04947319
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 119 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 29, 2021 (Actual)
- Primary completion
- Jan 27, 2026 (Actual)
- Completion
- Mar 31, 2027 (Estimated)
- Last update posted
- Mar 30, 2026
2021 – 2027
United States locations
- U.S. sites
- 39
- U.S. states
- 25
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham School of Medicine | Birmingham | Alabama | 35233 | — |
| Mayo Clinic- Phoenix | Phoenix | Arizona | 85054 | — |
| City of Hope Comprehensive Breast Cancer Center | Duarte | California | 91010 | — |
| University of California, Irvine | Irvine | California | 92868 | — |
| Stanford University | Palo Alto | California | 94304 | — |
| University of Colorado Denver | Aurora | Colorado | 80045 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| Georgetown University, Lombardi Comprehensive Cancer Center | Washington D.C. | District of Columbia | 20037 | — |
| Mayo Clinic- Jacksonville | Jacksonville | Florida | 32224 | — |
| University of Miami-Sylvester Cancer Center | Miami | Florida | 33136 | — |
| Orlando Health | Orlando | Florida | 32806 | — |
| Moffitt Cancer Center- Miami | Pembroke Pines | Florida | 33028 | — |
| Piedmont Healthcare | Atlanta | Georgia | 30318 | — |
| University of Kentucky | Lexington | Kentucky | 40536 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana-Farber Cancer Institute - Brigham & Women's Hospital Brigham and Women's Hospital | Boston | Massachusetts | 02215 | — |
| University Of Michigan | Ann Arbor | Michigan | 41809 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North | Kansas City | Missouri | 64154 | — |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | — |
| Hackensack University Medical Center - John Theurer Cancer | Hackensack | New Jersey | 07601 | — |
| Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI)) | Buffalo | New York | 14263 | — |
| Memorial Sloan Kettering | New York | New York | 10022 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Levine Cancer Center | Charlotte | North Carolina | 28204 | — |
| Duke University School of Medicine | Durham | North Carolina | 27705 | — |
| Cleveland Clinic | Cleveland | Ohio | 44106 | — |
| Providence Health Cancer Center | Portland | Oregon | 97239 | — |
| Penn State Hershey Cancer Center | Hershey | Pennsylvania | 17033 | — |
| Abramson Cancer Center University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Hillman Cancer Center, University of Pittsburgh | Pittsburgh | Pennsylvania | 15232 | — |
| Lifespan Rhode Island Hospital | Providence | Rhode Island | 02903 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | — |
| Houston Methodist Research Institute (HMRI) | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| The University of Utah - Huntsman Cancer Institute (HCI) | Salt Lake City | Utah | 84112 | — |
| The University of Vermont - Fletcher Allen Health Care | Burlington | Vermont | 05401 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04947319, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04947319 live on ClinicalTrials.gov.